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1. Introduction 
 
Sepsis is a systemic inflammatory response to infection in which the balance of pro- and 
anti-inflammatory mediators, which normally isolate and eliminate infection, is disrupted 
[1]. Gram negative sepsis is initiated by bacterial endotoxin release which activates 
macrophages and circulating monocytes to release TNF and IL-1β followed by IL-6 and 
other inflammatory cytokines [2]. As the disease progresses, an unregulated 
inflammatory response results in, tissue injury, haematological dysfunction and organ 
dysfunction. Severe sepsis, involving organ hypoperfusion may be further complicated 
by hypotension that is unresponsive to adequate fluid replacement, resulting in septic 
shock and finally death [3]. 
Despite improvements in anti-microbial and supportive therapies, sepsis remains a 
significant cause of morbidity and mortality in ICUs worldwide [4]. The complexity of 
processes mediating the progression of sepsis suggests that an extracorporeal device 
combining blood filtration with adsorption of a wide range of toxins, and inflammatory 
mediators offers the most comprehensive treatment strategy. However, no such device 
exists at present. A novel, uncoated, polymer pyrolysed synthetic carbon device is 
proposed which combines the superior adsorption properties of uncoated activated 
carbons with the capacity to manipulate porous structure for controlled adsorption of 
target plasma proteins and polypeptides [5]. Preliminary haemocompatibility and 
adsorptive capacity was assessed using a carbon matrix prototype.  
 
2. Experimental 
 
2.1 Material synthesis 
Novel phenol-formaldehyde-aniline based pyrolysed carbons were synthesised using 
monolithic polymer technology patented to Mast Carbon Ltd. Carbon wells of 19 mm 
diameter (figure 1) were manufactured for preliminary in vitro testing of carbon 
biocompatibility and adsorption/filtration capacity. Carbon well A exhibits a mainly 
microporous structure, Carbon wells B-D have an increasing ratio of mesoporous : 
microporous structure as displayed in figure 2..  
 
Fig 1. Carbon well (19mm diameter).        Fig 2. SEM of internal pore structure  
        (mag x 1000). 
 
2.2  Cytokine spiked-plasma adsorption assay. 
Fresh frozen human plasma (NBS) was defrosted and spiked with the recombinant 
human cytokines; TNF, IL6 & IL8 (BD Biosciences) at a concentration of 1000, 2000 
and 500pg/ml respectively. The levels are comparable to those measured in the plasma 
of sepsis patients [6]. Spiked plasma (1.8ml) was added to the surface of the carbon 
wells and tissue culture (tc) plastic controls, prior to incubation overnight at 37°C. 
Filtrate samples were collected from the base of the carbon wells and tc controls and 
stored at -20°C. Samples were diluted 1:8 (TNF,IL8) and 1:20 (IL6) in assay diluent, 
prior to the analysis of cytokine concentration using ELISAs (BD Biosciences). 
 
3. Results and Discussion 
 
Figure 3, indicates that all three cytokines (TNF,IL6 & IL8) when present in human 
plasma are removed to some extent by filtration/adsorption when allowed to flow 
through the carbon wells A-D. The largely microporous structure of Carbon well A, 
suggests why it is more successful in removing the smallest cytokine IL8 (8 kDa) from 
plasma. Whereas TNF (17kDa) forms a biologically active trimer and IL6 (21-28 kDa) 
complexes with proteins such as Alpha 2M when in plasma, thus both these cytokines 
exhibit a larger molecular size. As the results if figure 4 indicate, the more mesoporous 
carbon wells C&D display greater % removal from plasma of these two cytokines. 
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Fig 3. Carbon well adsorption/filtration of the cytokines TNF, IL6 & IL8 in human plasma. 
Plasma spiked with cytokines was collected after filtration through the carbon wells A-D, 
and assayed for cytokine concentration by ELISA. (n=3, mean +/- SEM). 
 
Cytokine 
Initial conc in 
plasma (pg/ml) 
% removed 
from plasma by 
Carbon well A 
% removed 
from plasma by 
Carbon well B 
% removed 
from plasma by 
Carbon well C 
% removed 
from plasma by 
Carbon well D 
TNF 1926.25 10.93 32.86 78.20 85.01 
IL6 2177.24 30.20 88.85 90.86 95.82 
IL8 520.71 69.30 100 100 100 
Fig 4. Carbon well adsorption/filtration of the cytokines TNF, IL6 & IL8 in human plasma. 
Data displays the % of each cytokine removed from the plasma by each carbon well A-
D (n=3). 
 
3. Conclusion 
 
Current haemoperfusion adsorbents suffer from a number of inherent problems. They 
have low affinities for the major pro-inflammatory cytokines and the amberlite-type 
adsorbents have a very broad pore size distribution, rendering them non-selective on 
the basis of molecular size. Finally, all the adsorbents are poorly biocompatible (7) and 
coating the carbons to avoid direct blood contact effectively inhibits the adsorption of 
molecules with larger molecular weights. 
The results obtained in our preliminary studies using the uncoated carbon well 
prototypes, conclude that by manipulation of the porous composition of the carbon 
matrix to create a differing mesoporous/microporous structure for our proposed device. 
We will be able to tailor the device for maximal adsorption/filtration of pro-inflammatory 
cytokines or bacterial toxins, which supports the further development of this device for 
the treatment of sepsis.   
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